{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:18Z","timestamp":1789948818447,"version":"4.0.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100003135","name":"Minnesota Ovarian Cancer Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003135","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001642","name":"Glenn Foundation for Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001642","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02870-7","type":"journal-article","created":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T23:03:26Z","timestamp":1789945406000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["BCLXL blockade rewires cell fate to overcome PARP inhibitor resistance in ovarian cancer"],"prefix":"10.1038","volume":"11","author":[{"given":"Annapoorna","family":"Venkatachalam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabella R.","family":"Strathman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianon","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Correia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X. Wei","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cordelia D.","family":"McGehee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily A.","family":"Balczewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura N.","family":"Duffield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia K.","family":"Rossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiming","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel M.","family":"Hurley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill M.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saloni","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen S.","family":"Flatten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula A.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana B.","family":"De Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa C.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann L.","family":"Oberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea E.","family":"Wahner Hendrickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhilesh","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5957-5472","authenticated-orcid":false,"given":"Hu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. John","family":"Weroha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4900-7145","authenticated-orcid":false,"given":"Scott H.","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"2870_CR1","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","volume":"33","author":"B Kaufman","year":"2015","unstructured":"Kaufman, B. et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation. J. Clin. Oncol. 33, 244\u2013250 (2015).","journal-title":"J. Clin. Oncol."},{"key":"2870_CR2","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ygyno.2020.09.006","volume":"159","author":"MR Mirza","year":"2020","unstructured":"Mirza, M. R. et al. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16\/NOVA trial. Gynecol. Oncol. 159, 442\u2013448 (2020).","journal-title":"Gynecol. Oncol."},{"key":"2870_CR3","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman, R. L. et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 1949\u20131961 (2017).","journal-title":"Lancet"},{"key":"2870_CR4","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1158\/1078-0432.CCR-16-2796","volume":"23","author":"R Kristeleit","year":"2017","unstructured":"Kristeleit, R. et al. A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1\/2-Mutated Ovarian Carcinoma or Other Solid Tumors. Clin. Cancer Res. 23, 4095\u20134106 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2870_CR5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","volume":"18","author":"EM Swisher","year":"2017","unstructured":"Swisher, E. M. et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 18, 75\u201387 (2017).","journal-title":"Lancet Oncol."},{"key":"2870_CR6","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917\u2013921 (2005).","journal-title":"Nature"},{"key":"2870_CR7","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1093\/nar\/gkad066","volume":"51","author":"N Laspata","year":"2023","unstructured":"Laspata, N. et al. PARP1 associates with R-loops to promote their resolution and genome stability. Nucleic Acids Res. 51, 2215\u20132237 (2023).","journal-title":"Nucleic Acids Res."},{"key":"2870_CR8","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai, J. et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res 72, 5588\u20135599 (2012).","journal-title":"Cancer Res"},{"key":"2870_CR9","doi-asserted-by":"crossref","unstructured":"Ribeiro, J. et al. Genetic evidence for PARP1 trapping as a driver of PARP inhibitor efficacy in BRCA mutant cancer cells. Nucleic Acids Res. 53, gkaf1398 (2025).","DOI":"10.1093\/nar\/gkaf1398"},{"key":"2870_CR10","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1158\/0008-5472.CAN-11-3417","volume":"72","author":"S Ying","year":"2012","unstructured":"Ying, S., Hamdy, F. C. & Helleday, T. Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1. Cancer Res 72, 2814\u20132821 (2012).","journal-title":"Cancer Res"},{"key":"2870_CR11","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1158\/0008-5472.CAN-20-1602","volume":"81","author":"NJ Panzarino","year":"2021","unstructured":"Panzarino, N. J. et al. Replication gaps underlie BRCA deficiency and therapy response. Cancer Res. 81, 1388\u20131397 (2021).","journal-title":"Cancer Res."},{"key":"2870_CR12","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41586-024-07217-2","volume":"628","author":"M Petropoulos","year":"2024","unstructured":"Petropoulos, M. et al. Transcription-replication conflicts underlie sensitivity to PARP inhibitors. Nature 628, 433\u2013441 (2024).","journal-title":"Nature"},{"key":"2870_CR13","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nrm2312","volume":"9","author":"RC Taylor","year":"2008","unstructured":"Taylor, R. C., Cullen, S. P. & Martin, S. J. Apoptosis: controlled demolition at the cellular level. Nat. Rev. Mol. Cell Biol. 9, 231\u2013241 (2008).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2870_CR14","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41580-023-00689-6","volume":"25","author":"J Yuan","year":"2024","unstructured":"Yuan, J. & Ofengeim, D. A guide to cell death pathways. Nat. Rev. Mol. Cell Biol. 25, 379\u2013395 (2024).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2870_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.cell.2023.11.044","volume":"187","author":"K Newton","year":"2024","unstructured":"Newton, K., Strasser, A., Kayagaki, N. & Dixit, V. M. Cell death. Cell 187, 235\u2013256 (2024).","journal-title":"Cell"},{"key":"2870_CR16","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/s41418-025-01481-z","volume":"32","author":"CM Croce","year":"2025","unstructured":"Croce, C. M. et al. The BCL-2 protein family: from discovery to drug development. Cell Death Differ. 32, 1369\u20131381 (2025).","journal-title":"Cell Death Differ."},{"key":"2870_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10460-1","volume":"10","author":"H Fleury","year":"2019","unstructured":"Fleury, H. et al. Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence. Nat. Commun. 10, 2556 (2019).","journal-title":"Nat. Commun."},{"key":"2870_CR18","doi-asserted-by":"crossref","unstructured":"Wyld, L. et al. Senescence and cancer: a review of clinical implications of senescence and senotherapies. Cancers (Basel) 12, 2134 (2020).","DOI":"10.3390\/cancers12082134"},{"key":"2870_CR19","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1126\/science.adj7050","volume":"384","author":"JP de Magalhaes","year":"2024","unstructured":"de Magalhaes, J. P. Cellular senescence in normal physiology. Science 384, 1300\u20131301 (2024).","journal-title":"Science"},{"key":"2870_CR20","doi-asserted-by":"publisher","first-page":"37813","DOI":"10.1074\/jbc.M110.200675","volume":"286","author":"S Achuthan","year":"2011","unstructured":"Achuthan, S., Santhoshkumar, T. R., Prabhakar, J., Nair, S. A. & Pillai, M. R. Drug-induced senescence generates chemoresistant stemlike cells with low reactive oxygen species. J. Biol. Chem. 286, 37813\u201337829 (2011).","journal-title":"J. Biol. Chem."},{"key":"2870_CR21","doi-asserted-by":"crossref","unstructured":"Paffenholz, S. V. et al. Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer. Proc. Natl. Acad. Sci. USA 119, e2117754119 (2022).","DOI":"10.1073\/pnas.2117754119"},{"key":"2870_CR22","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/onc.2013.96","volume":"33","author":"S Zhang","year":"2014","unstructured":"Zhang, S. et al. Generation of cancer stem-like cells through the formation of polyploid giant cancer cells. Oncogene 33, 116\u2013128 (2014).","journal-title":"Oncogene"},{"key":"2870_CR23","doi-asserted-by":"crossref","unstructured":"Harrington B. S., Annunziata C. M. NF-kappaB signaling in ovarian cancer. Cancers (Basel) 11, 1182 (2019).","DOI":"10.3390\/cancers11081182"},{"key":"2870_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41568-021-00407-4","volume":"22","author":"ST Diepstraten","year":"2022","unstructured":"Diepstraten, S. T. et al. The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. Nat. Rev. Cancer 22, 45\u201364 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"2870_CR25","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nature08822","volume":"463","author":"R Beroukhim","year":"2010","unstructured":"Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899\u2013905 (2010).","journal-title":"Nature"},{"key":"2870_CR26","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/943648","volume":"2014","author":"M Vogler","year":"2014","unstructured":"Vogler, M. Targeting BCL2-proteins for the treatment of solid tumours. Adv. Med. 2014, 943648 (2014).","journal-title":"Adv. Med."},{"key":"2870_CR27","doi-asserted-by":"publisher","first-page":"104547","DOI":"10.1016\/j.phrs.2019.104547","volume":"151","author":"M Li","year":"2020","unstructured":"Li, M., Wang, D., He, J., Chen, L. & Li, H. Bcl-X(L): a multifunctional anti-apoptotic protein. Pharmacol. Res. 151, 104547 (2020).","journal-title":"Pharmacol. Res."},{"key":"2870_CR28","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.12688\/f1000research.9629.1","volume":"5","author":"H Dai","year":"2016","unstructured":"Dai, H., Meng, X. W. & Kaufmann, S. H. Mitochondrial apoptosis and BH3 mimetics. F1000Res 5, 2804 (2016).","journal-title":"F1000Res"},{"key":"2870_CR29","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1158\/1541-7786.MCR-18-1243","volume":"17","author":"EH Stover","year":"2019","unstructured":"Stover, E. H. et al. Pooled genomic screens identify anti-apoptotic genes as targetable mediators of chemotherapy resistance in ovarian cancer. Mol. Cancer Res. 17, 2281\u20132293 (2019).","journal-title":"Mol. Cancer Res."},{"key":"2870_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04073-0","volume":"12","author":"D Liu","year":"2021","unstructured":"Liu, D. et al. Constitutive BAK\/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer. Cell Death Dis. 12, 789 (2021).","journal-title":"Cell Death Dis."},{"key":"2870_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11190","volume":"7","author":"R Yosef","year":"2016","unstructured":"Yosef, R. et al. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat. Commun. 7, 11190 (2016).","journal-title":"Nat. Commun."},{"key":"2870_CR32","doi-asserted-by":"publisher","first-page":"7191","DOI":"10.1158\/1078-0432.CCR-07-0362","volume":"13","author":"J Witham","year":"2007","unstructured":"Witham, J. et al. The Bcl-2\/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clin. Cancer Res. 13, 7191\u20137198 (2007).","journal-title":"Clin. Cancer Res."},{"key":"2870_CR33","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nm.4010","volume":"22","author":"J Chang","year":"2016","unstructured":"Chang, J. et al. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat. Med. 22, 78\u201383 (2016).","journal-title":"Nat. Med."},{"key":"2870_CR34","doi-asserted-by":"publisher","first-page":"111826","DOI":"10.1016\/j.celrep.2022.111826","volume":"41","author":"V Bharti","year":"2022","unstructured":"Bharti, V. et al. BCL-xL inhibition potentiates cancer therapies by redirecting the outcome of p53 activation from senescence to apoptosis. Cell Rep. 41, 111826 (2022).","journal-title":"Cell Rep."},{"key":"2870_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/narcan\/zcab028","volume":"3","author":"RM Hurley","year":"2021","unstructured":"Hurley, R. M. et al. Characterization of a RAD51C-silenced high grade serous ovarian cancer model during development of PARP inhibitor resistance. NAR Cancer 3, zcab028 (2021).","journal-title":"NAR Cancer"},{"key":"2870_CR36","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf7195","volume":"9","author":"X Zhang","year":"2023","unstructured":"Zhang, X. et al. Targeting polyploid giant cancer cells potentiates a therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer. Sci. Adv. 9, eadf7195 (2023).","journal-title":"Sci. Adv."},{"key":"2870_CR37","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123\u2013134 (2009).","journal-title":"N. Engl. J. Med."},{"key":"2870_CR38","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1084\/jem.182.5.1545","volume":"182","author":"SJ Martin","year":"1995","unstructured":"Martin, S. J. et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J. Exp. Med 182, 1545\u20131556 (1995).","journal-title":"J. Exp. Med"},{"key":"2870_CR39","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/cdd.2012.93","volume":"20","author":"SH Lee","year":"2013","unstructured":"Lee, S. H., Meng, X. W., Flatten, K. S., Loegering, D. A. & Kaufmann, S. H. Phosphatidylserine exposure during apoptosis reflects bidirectional trafficking between plasma membrane and cytoplasm. Cell Death Differ. 20, 64\u201376 (2013).","journal-title":"Cell Death Differ."},{"key":"2870_CR40","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1158\/1078-0432.CCR-10-1382","volume":"17","author":"U Kortmann","year":"2011","unstructured":"Kortmann, U. et al. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clin. Cancer Res. 17, 783\u2013791 (2011).","journal-title":"Clin. Cancer Res."},{"key":"2870_CR41","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1158\/1078-0432.CCR-11-2890","volume":"18","author":"AG Patel","year":"2012","unstructured":"Patel, A. G., De Lorenzo, S. B., Flatten, K. S., Poirier, G. G. & Kaufmann, S. H. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro. Clin. Cancer Res. 18, 1655\u20131662 (2012).","journal-title":"Clin. Cancer Res."},{"key":"2870_CR42","doi-asserted-by":"publisher","first-page":"25543","DOI":"10.1074\/jbc.274.36.25543","volume":"274","author":"H Goto","year":"1999","unstructured":"Goto, H. et al. Identification of a novel phosphorylation site on histone H3 coupled with mitotic chromosome condensation. J. Biol. Chem. 274, 25543\u201325549 (1999).","journal-title":"J. Biol. Chem."},{"key":"2870_CR43","doi-asserted-by":"publisher","first-page":"6381","DOI":"10.1158\/0008-5472.CAN-09-1178","volume":"69","author":"W Sakai","year":"2009","unstructured":"Sakai, W. et al. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res 69, 6381\u20136386 (2009).","journal-title":"Cancer Res"},{"key":"2870_CR44","doi-asserted-by":"crossref","unstructured":"McGehee, C. D. et al. Codon specific readthrough as a mechanism of BRCA2 restoration in acquired PARP inhibitor and chemotherapy resistance. Nucleic Acids Res. 53, gkaf990 (2025).","DOI":"10.1093\/nar\/gkaf990"},{"key":"2870_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-59074-4","volume":"10","author":"AA Antolin","year":"2020","unstructured":"Antolin, A. A. et al. The kinase polypharmacology landscape of clinical PARP inhibitors. Sci. Rep. 10, 2585 (2020).","journal-title":"Sci. Rep."},{"key":"2870_CR46","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/j.chembiol.2016.10.011","volume":"23","author":"CE Knezevic","year":"2016","unstructured":"Knezevic, C. E. et al. Proteome-wide profiling of clinical PARP inhibitors reveals compound-specific secondary targets. Cell Chem. Biol. 23, 1490\u20131503 (2016).","journal-title":"Cell Chem. Biol."},{"key":"2870_CR47","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/s10495-016-1339-x","volume":"22","author":"C Cardenas","year":"2017","unstructured":"Cardenas, C. et al. Adipocyte microenvironment promotes Bcl(xl) expression and confers chemoresistance in ovarian cancer cells. Apoptosis 22, 558\u2013569 (2017).","journal-title":"Apoptosis"},{"key":"2870_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02125-5","volume":"23","author":"A Venkatachalam","year":"2024","unstructured":"Venkatachalam, A. et al. Proapoptotic activity of JNK-sensitive BH3-only proteins underpins ovarian cancer response to replication checkpoint inhibitors. Mol. Cancer 23, 224 (2024).","journal-title":"Mol. Cancer"},{"key":"2870_CR49","doi-asserted-by":"crossref","unstructured":"da Costa, A., Chowdhury, D., Shapiro, G. I., D\u2019Andrea, A. D., Konstantinopoulos, P. A. Targeting replication stress in cancer therapy. Nat. Rev. Drug Discov. 22, 38\u201358 (2022).","DOI":"10.1038\/s41573-022-00558-5"},{"key":"2870_CR50","doi-asserted-by":"publisher","first-page":"279ra240","DOI":"10.1126\/scitranslmed.aaa4642","volume":"7","author":"JD Leverson","year":"2015","unstructured":"Leverson, J. D. et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci. Transl. Med. 7, 279ra240 (2015).","journal-title":"Sci. Transl. Med."},{"key":"2870_CR51","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ygyno.2016.08.328","volume":"143","author":"HilliMM Al","year":"2016","unstructured":"Al, H. illiM. M. et al. In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma. Gynecol. Oncol. 143, 379\u2013388 (2016).","journal-title":"Gynecol. Oncol."},{"key":"2870_CR52","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.22.01549","volume":"41","author":"P DiSilvestro","year":"2023","unstructured":"DiSilvestro, P. et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial. J. Clin. Oncol. 41, 609\u2013617 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2870_CR53","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","volume":"35","author":"BJ Monk","year":"2024","unstructured":"Monk, B. J. et al. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial. Ann. Oncol. 35, 981\u2013992 (2024).","journal-title":"Ann. Oncol."},{"key":"2870_CR54","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ygyno.2019.10.023","volume":"156","author":"SC Cecere","year":"2020","unstructured":"Cecere, S. C. et al. Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: real world data and post progression outcome. Gynecol. Oncol. 156, 38\u201344 (2020).","journal-title":"Gynecol. Oncol."},{"key":"2870_CR55","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ygyno.2019.01.015","volume":"153","author":"RM Hurley","year":"2019","unstructured":"Hurley, R. M. et al. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer. Gynecol. Oncol. 153, 127\u2013134 (2019).","journal-title":"Gynecol. Oncol."},{"key":"2870_CR56","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord, C. J. & Ashworth, A. PARP inhibitors: Synthetic lethality in the clinic. Science 355, 1152\u20131158 (2017).","journal-title":"Science"},{"key":"2870_CR57","doi-asserted-by":"publisher","first-page":"4206","DOI":"10.1158\/1078-0432.CCR-19-4121","volume":"26","author":"S Lheureux","year":"2020","unstructured":"Lheureux, S. et al. EVOLVE: A multicenter open-label single-arm clinical and translational phase II Trial of cediranib plus olaparib for ovarian cancer after PARP inhibition progression. Clin. Cancer Res. 26, 4206\u20134215 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2870_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22582-6","volume":"12","author":"EM Swisher","year":"2021","unstructured":"Swisher, E. M. et al. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nat. Commun. 12, 2487 (2021).","journal-title":"Nat. Commun."},{"key":"2870_CR59","doi-asserted-by":"publisher","first-page":"1354427","DOI":"10.3389\/fonc.2024.1354427","volume":"14","author":"L Collet","year":"2024","unstructured":"Collet, L. et al. BRCA1\/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges. Front Oncol. 14, 1354427 (2024).","journal-title":"Front Oncol."},{"key":"2870_CR60","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S1097-2765(00)80456-6","volume":"3","author":"H Puthalakath","year":"1999","unstructured":"Puthalakath, H., Huang, D. C. S., O\u2019Reilly, L. A., King, S. M. & Strasser, A. The proapoptotic activity of the Bcl-2 family member bim is regulated by interaction with the dynein motor complex. Mol. Cell 3, 287\u2013296 (1999).","journal-title":"Mol. Cell"},{"key":"2870_CR61","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.cell.2015.01.042","volume":"160","author":"J Montero","year":"2015","unstructured":"Montero, J. et al. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell 160, 977\u2013989 (2015).","journal-title":"Cell"},{"key":"2870_CR62","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41698-025-00947-0","volume":"9","author":"EPB Rodman","year":"2025","unstructured":"Rodman, E. P. B. et al. Lestaurtinib\u2019s antineoplastic activity converges on JAK\/STAT signaling to inhibit treatment naive and therapy resistant forms ovarian cancer. npj Precis. Oncol. 9, 236 (2025).","journal-title":"npj Precis. Oncol."},{"key":"2870_CR63","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1182\/blood.V89.6.2098","volume":"89","author":"SH Kaufmann","year":"1997","unstructured":"Kaufmann, S. H. et al. Altered Formation of Topotecan-Stabilized Topoisomerase I-DNA Adducts in Human Leukemia Cells. Blood 89, 2098\u20132104 (1997).","journal-title":"Blood"},{"key":"2870_CR64","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1006\/abio.2001.5313","volume":"296","author":"SH Kaufmann","year":"2001","unstructured":"Kaufmann, S. H. Reutilization of Immunoblots After Chemiluminescent Detection. Anal. Biochem 296, 283\u2013286 (2001).","journal-title":"Anal. Biochem"},{"key":"2870_CR65","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1101\/gad.267997.115","volume":"29","author":"H Dai","year":"2015","unstructured":"Dai, H. et al. Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells. Genes Dev. 29, 2140\u20132152 (2015).","journal-title":"Genes Dev."},{"key":"2870_CR66","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1074\/jbc.M106287200","volume":"277","author":"WA Cliby","year":"2002","unstructured":"Cliby, W. A., Lewis, K. A., Lilly, K. K. & Kaufmann, S. H. S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function. J. Biol. Chem. 277, 1599\u20131606 (2002).","journal-title":"J. Biol. Chem."},{"key":"2870_CR67","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"T-C Chou","year":"1984","unstructured":"Chou, T.-C. & Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzym. Reg. 22, 27\u201355 (1984).","journal-title":"Adv. Enzym. Reg."},{"key":"2870_CR68","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0031-6997(25)00026-2","volume":"41","author":"MC Berenbaum","year":"1989","unstructured":"Berenbaum, M. C. What is Synergy? Pharmacol. Rev. 41, 93\u2013141 (1989).","journal-title":"Pharmacol. Rev."},{"key":"2870_CR69","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1158\/1078-0432.CCR-13-2611","volume":"20","author":"SJ Weroha","year":"2014","unstructured":"Weroha, S. J. et al. Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clin. Cancer Res. 20, 1288\u20131297 (2014).","journal-title":"Clin. Cancer Res."},{"key":"2870_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-87470-x","volume":"11","author":"AL Oberg","year":"2021","unstructured":"Oberg, A. L. et al. Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting. Sci. Rep. 11, 8076 (2021).","journal-title":"Sci. Rep."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02870-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02870-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02870-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T23:03:29Z","timestamp":1789945409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02870-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2870"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02870-7","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"393"}}